Tradestie Institutional Equity Comparison Engine

PLRX vs LYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PLRX Overall Edge

PLRX Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pliant Therapeutics, Inc. Common Stock (PLRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PLRX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, PLRX sits in UNCLASSIFIED (4th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
PLRX N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner PLRX
Op Margin 0.0% vs -25032.0% ยท YoY -100.0% vs -87.2%
Momentum & Technical Winner PLRX
1Y -60.9% vs -94.3% ยท 52W Pos 0% vs 1%
Options & Structure Winner PLRX
UNCLASSIFIED (4th %ile IV) vs UNCLASSIFIED (N/A IV)
PLRX NASDAQ
Pliant Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.66
-5.16% 1D
Market Cap $43.2M
1M Return -26.84%
1Y Return -60.87%
Forward P/E N/M
Unified AI Score
39.0 / 100 SELL
Tech 25.0 Fund 43.0 Flow 63.0 Mom 44.0
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PLRX -60.87% LYRA -94.34% Spread: +65.12 pp (PLRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PLRX Revenue LYRA Revenue PLRX Op. Margin LYRA Op. Margin Margin Edge
FY2019 $60M N/A -2.2% N/A PLRX
FY2020 $40M N/A -99.6% N/A PLRX
FY2021 $10M $0M -1288.1% -15303.5% PLRX
FY2022 $10M $0M -1313.4% -4131.0% PLRX
FY2023 $0M $0M -11654.7% -4308.1% LYRA
FY2024 N/A $0M N/A -6280.8% LYRA
FY2025 N/A $0M N/A -7794.5% LYRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PLRX (4) vs LYRA (3)
Institutional Metric PLRX LYRA Criterion Row Winner
Market Capitalization Scale $43.2M $2.3M Larger Scale PLRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% -87.2% Higher Growth LYRA
Operating Margin (TTM) Profitability 0.0% -25032.0% Higher Margin PLRX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -50.3% -404.5% Higher ROE PLRX
52-Week Range Position Momentum 0% ($1โ€“$2) 1% ($0โ€“$38) Stronger Trend LYRA
Beta / 30D Volatility Risk Regime 0.93ฮฒ ยท 37% Vol 0.33ฮฒ ยท 248% Vol Lower Realized Risk PLRX
Unified Institutional Score Composite Signal 39.0 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PLRX vs LYRA Buy Guide
PLRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live PLRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PLRX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.